Ratings Bayer AG Deutsche Boerse AG

Equities

BAYN

DE000BAY0017

Market Closed - Deutsche Boerse AG Other stock markets 12:53:44 29/06/2024 am IST			5-day change	1st Jan Change
26.32 ^EUR	+0.88%		+0.80%	-21.91%

28/06	Borse Frankfurt-News: Uncertainty ahead of French election (Bond Trading)	DP
27/06	Chemicals collective agreement: Bonus days for union members	DP

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

With a P/E ratio at 11.09 for the current year and 7.98 for next year, earnings multiples are highly attractive compared with competitors.
The company appears to be poorly valued given its net asset value.
Given the positive cash flows generated by its business, the company's valuation level is an asset.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
For the past year, analysts have significantly revised downwards their profit estimates.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Over the past twelve months, analysts' opinions have been revised negatively.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
BAYER AG	-21.91%	27.77B	-
ELI LILLY AND COMPANY	+55.32%	815B	C+
NOVO NORDISK A/S	+44.05%	641B	B
JOHNSON & JOHNSON	-6.75%	352B	C+
MERCK & CO., INC.	+13.56%	314B	B-
ABBVIE INC.	+10.68%	303B	C+
ASTRAZENECA PLC	+16.57%	242B	B+
NOVARTIS AG	+13.31%	218B	B-
AMGEN INC.	+8.48%	168B	C+
PFIZER, INC.	-2.81%	159B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes